Authors
Latest:
Carmela Hoefling Discusses Effects of Malnutrition During SurgeryCarmela Hoefling, RN, MSN, APN-C, AOCNP, advanced practice nurse, Gastrointestinal/Hepatobiliary Oncology Program, Rutgers Cancer Institute of New Jersey, discusses the effects that malnourishment can have on surgery.
Latest:
Dr Brufsky on the Unique Design of the Allogeneic SV-BR-1-GM Vaccine in Metastatic Breast CancerAdam M. Brufsky, MD, PhD, FACP, discusses the unique design of the allogeneic GM-CSF–secreting breast cancer vaccine SV-BR-1-GM.
Latest:
Dr Cohen on Efforts Needed to Unmet Needs in R/R Multiple MyelomaAdam D. Cohen, MD, discusses unmet needs and areas for future investigation within the relapsed/refractory multiple myeloma treatment landscape.
Latest:
Dr. Adam Dicker on Combination Treatments With Radiation TherapyAdam Dicker, MD, PhD, professor, chair, department of Radiation Oncology Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses the potential for radiation combinations.
Latest:
Dr. Feldman on Link Between Obesity and Risk for RCCAdam S. Feldman, MD, MPH, urologist, Department of Urology, Massachusetts General Hospital, discusses the association between obesity and the risk of developing total and fatal renal cell carcinoma (RCC).
Latest:
Expanding Cancer Screening: The Future of Blood-Based TestingClosing out their panel, experts discuss the potential of blood-based tests to democratize access to cancer screening, complement existing protocols, and achieve early detection goals in the fight against cancer.
Latest:
Treatment Options for Patients with Stage III & IV Melanoma: Part II: Experimental treatments for stage III/IV or refractory/recurrent melanomaVarious immunotherapeutic strategies to treat advanced melanoma have been under investigation for more than a decade
Latest:
Dr. Waxman on the Future of Treatment in Multiple MyelomaAdam J. Waxman, MD, MS, assistant professor of clinical medicine, Penn Medicine, University of Pennsylvania, discusses the future of treatment in patients with multiple myeloma.
Latest:
Dr. Brufsky on the Utility of Zanidatamab in HER2+ Breast CancerAdam M. Brufsky, MD, PhD, FACP, discusses the unique mechanism of action of zanidatamab and encouraging efficacy observed in patients with HER2-positive breast cancer.
Latest:
Emerging Trials in the Management of HR+/HER2- Locally Advanced or Metastatic Breast CancerAdam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, share their perspectives on the future landscape of HR+/HER2- locally advanced or metastatic breast cancer treatment and provide essential insights to summarize the key points of their discussion.
Latest:
Dr. Dicker on DNA Sequencing for Prostate CancerAdam P. Dicker, MD, PhD, professor, chair, Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses DNA sequencing for patients with prostate cancer.
Latest:
Dr. Kibel on Take-Home Messages in Field of Genitourinary CancersAdam S. Kibel, MD, disease center leader, urology chief, urologic surgery, Brigham and Women's Hospital, professor of Surgery, Harvard Medical School, Dana-Farber Cancer Institute, discusses take-home messages for community oncologists out of the 2016 Genitourinary Cancers Symposium.
Latest:
Dr. Feldman on Men With Prostate Cancer Receiving Treatment After Active SurveillanceAdam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses men with prostate cancer receiving treatment after active surveillance.
Latest:
Dr. Kardosh Discusses Epacadostat in Gastric/GEJ AdenocarcinomaAdel Kardosh, MD, postdoctoral medical fellow, oncology, Stanford Medicine, discusses epacadostat in gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Latest:
Dr. Hormigo on the Current Treatment Landscape of GlioblastomaAdilia Hormigo, MD, PhD, discusses the current treatment landscape of glioblastoma.
Latest:
Dr. Aditi Kumar on Aggressive Multimodal Therapy in Anaplastic Thyroid CancerAditi Kumar, MD, endocrinology fellow at the University of Mississippi, discusses aggressive multimodal therapy in anaplastic thyroid cancer. A study conducted at the Mayo Clinic, where Kumar was previously a fellow, looked at 29 patients with stage IV, A, B and C anaplastic thyroid cancer, a rare form of thyroid cancer with poor outcomes. Often, patients are not treated at this stage, as options are limited and toxicities from treatments can be high, says Kumar.
